2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Molecular Testing, Clinical Procedures, Treatment Considerations, Combination Therapy, Supportive Care, Biological Therapies, Non-Biological Therapies, Chemotherapy, Adverse Events, Artificial Intelligence (AI), Machine Learning, Biological Processes, Immune Mechanism, Molecular Biology, Clinical Practice (Health Services and Quality), Patient Safety, Practice Models, Value, Diseases, Bleeding and Clotting, Immunology, Infectious Diseases, Fungal, Lymphoid Malignancies, Lymphoid Leukemias, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, ALL, Research, AML, Translational Research, MDS, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly, Pediatric, Young Adult
PAPER

1618 Participation in clinical trials and long-term outcomes of patients with AML and MDS who require interpreters

Suravi Raychaudhuri, MD, Megan Othus, PhD2, Kathryn (Katie) D. Russell, ARNP3, Carole Shaw4, Rutu Vyas5, Olivia Halle6, Ruby Wacker7, Chiara Lucia Perni, N/A8, Paul Hendrie, MD, PHD9, Raya Mawad, MD10, Cristina Maria Ghiuzeli, MD11, Ryan D. Cassaday, MD12, Anna Halpern, MD13, Jacob Appelbaum, MD/PhD14, Mary-Elizabeth Percival, MD15
1 Fred Hutchinson Cancer Center, Seattle, Washington, United States, University of Washington, Seattle, Washington, United States
2 Fred Hutchinson Cancer Center, Seattle, Washington, United States
3 Fred Hutchinson Cancer Center, Seattle, Washington, United States, University of Washington, Seattle, Washington, United States
4 Fred Hutchinson Cancer Center, Seattle, Washington, United States
5 Fred Hutchinson Cancer Center, Seattle, Washington, United States
6 University of Washington, Seattle, Washington, United States
7 University of Washington, Seattle, Washington, United States
8 University of Washington, Seattle, Washington, United States
9 Fred Hutchinson Cancer Center, Seattle, Washington, United States, University of Washington, Seattle, Washington, United States
10 Fred Hutchinson Cancer Center, Seattle, Washington, United States, University of Washington, Seattle, Washington, United States
11 Fred Hutchinson Cancer Center, Seattle, Washington, United States, University of Washington, Seattle, Washington, United States
12 Fred Hutchinson Cancer Center, Seattle, Washington, United States, University of Washington, Seattle, Washington, United States
13 Fred Hutchinson Cancer Center, Seattle, Washington, United States, University of Washington, Seattle, Washington, United States
14 Fred Hutchinson Cancer Center, Seattle, Washington, United States, University of Washington, Seattle, Washington, United States
15 Fred Hutchinson Cancer Center, Seattle, Washington, United States, University of Washington, Seattle, Washington, United States

Introduction

Language barriers may affect access to care and outcomes in patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Management of these hematologic malignancies requires complex shared decision making with patients and caregivers. Participation in clinical trials is recommended by national guidelines for many clinical scenarios. In this single-center retrospective cohort analysis, we compared rates of participation in clinical trials and long-term outcomes in patients who required interpreter services to those who did not.

Methods

The study cohort included all patients with diagnosis of AML or high-grade myeloid neoplasms (≥10% blasts in blood or marrow) who were treated at University of Washington/Fred Hutchinson Cancer Center from 3/2021 to 11/2025. Patients were identified as requiring an interpreter if the patient or patient’s primary caretaker had a preferred language other than English as recorded in the electronic medical record (EMR).  Demographics, disease related characteristics, and clinical outcomes were obtained from the EMR. Multivariable regression models were adjusted for age, diagnosis (AML versus MDS), race, ethnicity, European LeukemiaNet (ELN) 2022 risk classification, and treatment‑related mortality (TRM) score (https://trmcalculator.fredhutch.org/). TRM score estimates risk of death 28 days from initiation of chemotherapy in newly diagnosed AML (Walter, JCO, 2011). Clinical trial enrollment rates included both observational and interventional trials.

Results

The study cohort included 1043 patients; 48 (4.6%) patients required interpreters, 2 (0.2%) had a primary caretaker who required an interpreter, and 993 (95.2%) did not require an interpreter. Median follow up time was 1.9 years. Nineteen non‑English languages were represented: Spanish (n=15), Russian (6), Mandarin (5), Cambodian/Khmer (4), Vietnamese (4), Amharic (2), Korean (2), Cantonese (1), Armenian (1), Farsi/Persian (1), French (1), Gujarati (1), Marshallese (1), Mien (1), Polish (1), Tagalog (1), Tongan (1), Taiwanese (1), and Ukrainian (1). Fourty-four (88%) of the patients in the interpreter group had a diagnosis of AML, versus 771 (78%) of those in the non-interpreter group (p=0.26). ELN risk classification and TRM scores were not significantly different between the interpreter and non‑interpreter groups (p=0.82, p=0.61 respectively).

Clinical trial enrollment rates differed significantly by interpreter status. 30% (15/50) of patients requiring an interpreter enrolled in a clinical trial compared with 51% (502/993) of those who did not (p=0.006). In a multivariable logistic regression model controlling for age, diagnosis, race, ethnicity, ELN risk, and TRM score, the odds of enrolling on a clinical trial were 2.71 (95% CI 1.34-5.49, p=0.006) times higher for patients who did not need an interpreter compared to those that did.

In multivariable Cox regression models, requiring an interpreter did not result in a significantly different overall survival (HR 1.05, 95% CI 0.65-1.69) or event-free survival (HR 1.26, 95% CI 0.85-1.86). Twenty (40%) patients in the interpreter group and 298 (30%) patients in the non‑interpreter group underwent allogeneic hematopoietic cell transplant (HCT), with median times to HCT of 5.0 and 5.6 months, respectively. In a multivariable cause-specific hazard model for time to allogeneic HCT, those that needed an interpreter did not have a significantly different time to HCT (HR 0.98, 95% CI 0.58-1.67).

Discussion

In this single-center cohort analysis of patients with AML and high-grade MDS, the need for an interpreter was not associated with worse overall survival, event-free survival, or delayed time to HCT. However, those who required interpreters were significantly less likely to participate in clinical trials. Further research is needed to identify specific logistical, financial, or cultural barriers that impair access to clinical trials for patients with limited English proficiency. Efforts to expand translated consent materials, ensure interpreter availability during trial screening, and design protocols inclusive of non‑English‑speaking patients may help address this gap in leukemia care.

Suravi Raychaudhuri, MD: No relevant conflicts of interest to declare.